45 Ovarian Function Suppression Plus Fulvestrant in Premenopausal Women with Metastatic Breast Cancer
Rupert Bartsch(Universitätszahnklinik Wien), G.G. Steger(National Cancer Center), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Anna S. Berghoff(Medical University of Vienna), P Dubsky, Florian Fitzal, Ursula Pluschnig(Medical University of Vienna), Robert M. Mader(Centre de Recherche en Économie et Management), C. Zielinski(Central European Cooperative Oncology Group), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 2
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830